2 Information about ozanimod

Marketing authorisation indication

2.1 Ozanimod (Zeposia, Celgene, a Bristol Myers Squibb Company) is indicated for 'the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics for ozanimod.


2.3 The price of an ozanimod induction pack is £343 (4 capsules of 0.23 mg and 3 capsules of 0.46 mg per pack). The price of a maintenance pack is £1,373 (0.92 mg, 28‑capsule pack) or £4,806 (0.92 mg, 98‑capsule pack; all prices excluding VAT; company submission). The estimated cost for the induction and maintenance phases of treatment is £17,910 per person per year (company submission, excluding VAT).

2.4 The company has a commercial arrangement. This makes ozanimod available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)